Why Attend the 17th World Bispecific Summit?
The 17th World Bispecific Summit US brings together a focused community of drug development experts across antibody discovery, protein engineering, biology, analytical development, developability assessment and early clinical development to tackle the challenges of multi-target design.
Through technical deep-dives, case studies and collaborative discussions, gain practical insights into optimizing bispecific formats, improving developability and translating complex biology into clinically viable drugs.
At this pivotal moment when key technological advancements are being made in advanced antibody design, join the leaders advancing next generation bispecifics and accelerating their path from pipelines to patients.
What’s New for 2026?
Attend the Deep Dive Seminar Day
Learn about sophisticated molecular architecture, developability and stability-led engineering to derisk downstream development with Merck, Amgen and Crescent Biopharma
Uncover Novel Targets
Identify first-in-class opportunities and explore mechanistic rationale for different target combinations to maximize therapeutic efficacy with NextPoint Therapeutics, Oxford Biotherapeutics, Oblenio Bio and IN8Bio
Understand Novel Masking & Co-Stimulation Approaches
Understand how novel masking and co-stimulation approaches drive therapeutic activity to improve therapeutic windows with Xilio Therapeutics, EvolveImmune Therapeutics and Rondo Therapeutics
Explore Complex Formats
Examine formats such as logic gated cell engagers and bispecific ADCs to overcome resistance, antigen escape and immune cell exhaustion with AstraZeneca, ImmuVia and ModeX Therapeutics
Modeling & Biomarker Strategies for Bispecifics
Leverage mechanistic modelling for dose selection and navigate future oncology and autoimmune directions for bispecifics using biomarker-led strategies with Takeda, Reverb Therapeutics and Amgen
Gather industry insights
Through discursive panel discussions, cover the trends, data gaps, strengths and weaknesses of the space, as well as data submission package differences for autoimmune versus cancer indications
Brand-New Companies for 2026